MRKMerck Sharp & Dohme LLCSigning up patients
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
Lung Neoplasm
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 144 (planned)
- Started
- May 28, 2025
- Main results expected
- Mar 2, 2032
- Fully finished
- Mar 2, 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response Rate (ORR)
Measured over: Up to approximately 81 months
Number of participants who experience one or more adverse events (AEs)
Measured over: Up to approximately 81 months
Number of participants who discontinue study intervention due to an AE
Measured over: Up to approximately 81 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06780098 · record last updated 2026-10-07 · checked 2026-11-09 15:47 UTC